SCHEMBL5249583

SCHEMBL5249583

Nc1onc2cccc(-c3ccc(NC(=O)Nc4ccc(F)c(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.73
FLT3 P36888 12/20 0.73
KIT P10721 12/20 0.73
RIPK1 Q13546 2/20 0.61
CSF1R P07333 2/20 0.56
FLT1 P17948 2/20 0.56
FLT4 P35916 2/20 0.56
RET P07949 1/20 0.56
FGFR1 P11362 1/20 0.56
FRK P42685 1/20 0.56
CAMK2B Q13554 1/20 0.56
CAMK2D Q13557 1/20 0.56
NTRK3 Q16288 1/20 0.56
HIPK4 Q8NE63 1/20 0.56
AURKB Q96GD4 1/20 0.56
ABL1 P00519 1/20 0.54
LCK P06239 1/20 0.54
LYN P07948 1/20 0.54
SRC P12931 1/20 0.54
BLK P51451 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379590 0.86 KDR (0.67) KDRFLT3KITRIPK1CSF1R
SCHEMBL4736486 0.86 KDR (0.72) KDRFLT3KITRIPK1CSF1R
SCHEMBL4740222 0.86 KDR (0.72) KDRFLT3KITCSF1RFLT1
SCHEMBL1384952 0.86 KDR (0.74) KDRFLT3KITRIPK1CSF1R
SCHEMBL4737823 0.86 KDR (0.70) KDRFLT3KITCSF1RFLT1
SCHEMBL4736538 0.85 KDR (0.72) KDRFLT3KITRIPK1CSF1R
SCHEMBL4739581 0.85 KDR (0.62) KDRFLT3KITRIPK1CSF1R
SCHEMBL4736063 0.85 KDR (0.70) KDRFLT3KITCSF1RFLT1
SCHEMBL422615 0.84 KIT (1.00) KDRFLT3KITCSF1RFLT1
SCHEMBL1382612 0.84 KDR (0.68) KDRFLT3KITCSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed